Digital Therapeutics Usage Data
Buy and sell digital therapeutics usage data data. App engagement, CBT module completion, symptom tracking — digital mental health AI needs real user journey data.
No listings currently in the marketplace for Digital Therapeutics Usage Data.
Find Me This Data →Overview
What Is Digital Therapeutics Usage Data?
Digital therapeutics usage data captures real-world patient engagement with therapeutic apps—including CBT module completion rates, symptom tracking patterns, and app interaction sequences. This data stream flows continuously from patient use, creating a rich longitudinal record of treatment adherence and clinical outcomes that traditional clinical trials cannot easily replicate. Manufacturers and AI developers use this data to validate efficacy claims, refine algorithms, and demonstrate real-world value to payers and regulators. The FDA, EMA, and Health Canada increasingly accept real-world data (RWD) from digital therapeutics to support both pre-market approval and post-market safety assessments, making usage metrics a critical regulatory and commercial asset.
Market Data
$50M Series C
Major Pharma Investment Signal
Source: Simon Kucher
Pharma, Insurance, Healthcare Companies
Active Investor Categories
Source: Simon Kucher
FDA, EMA, Health Canada support RWD
Regulatory Acceptance
Source: PubMed Central
Who Uses This Data
What AI models do with it.do with it.
Clinical Efficacy Validation
Manufacturers demonstrate real-world effectiveness outside controlled trial settings to payers and regulators, supporting value negotiations and coverage decisions.
Regulatory Submissions & Post-Market Surveillance
FDA and EMA now require or accept real-world usage data for drug approvals and ongoing safety monitoring, making continuous engagement metrics essential for compliance.
Algorithm Refinement & AI Training
Digital health companies use patient journey data—symptom progression, module completion, engagement patterns—to improve CBT algorithms and personalize treatment pathways.
Payer Pilot Programs & Risk Contracts
Insurance companies run pilot deployments to validate cost savings and patient outcomes before full plan coverage, using engagement data to structure innovative payment models.
What Can You Earn?
What it's worth.worth.
Anonymized Aggregated Datasets
Varies
Data packaged by therapeutic area (e.g., diabetes, mental health) sold to competing manufacturers seeking competitive intelligence and efficacy benchmarks.
Longitudinal Patient Cohorts
Varies
De-identified multi-month engagement and outcome records sold to AI/ML developers and clinical researchers validating digital health interventions.
Real-Time Engagement Feeds
Varies
Ongoing subscription access to anonymized usage streams for payers and manufacturers monitoring post-market efficacy and safety signals.
What Buyers Expect
What makes it valuable.valuable.
Data Standardization & Interoperability
Buyers require consistent data formats and standardized coding systems. Disparate hospital and clinic EHR systems often lack compatibility; harmonized datasets command premium pricing.
Robust Privacy & Regulatory Compliance
All datasets must be fully de-identified and compliant with GDPR, HIPAA, and sector-specific regulations. Buyers validate that collection and governance protocols meet FDA/EMA standards for regulatory submissions.
Device & Measurement Reliability
Data accuracy and consistency across platforms varies. Buyers favor datasets from validated, FDA-cleared apps with documented measurement protocols and low technical error rates.
Demographic Representativeness
Datasets reflecting diverse socioeconomic, geographic, and digital literacy populations command higher valuations. Data skewed toward high-access groups may be discounted or rejected.
Companies Active Here
Who's buying.buying.
Validate real-world efficacy of new drugs, train AI algorithms for companion apps, and support payer negotiations with clinical evidence.
Pilot digital therapeutics, measure cost savings and patient outcomes, structure risk-based contracts with providers and manufacturers.
Benchmark product performance, identify patient subgroups with best outcomes, and resell aggregated insights to competing manufacturers.
Evaluate safety and efficacy claims for product approval and post-market surveillance using real-world engagement and clinical outcome data.
FAQ
Common questions.questions.
What data points are most valuable in digital therapeutics datasets?
Module completion rates, symptom tracking frequency and accuracy, time-to-first-engagement, long-term adherence patterns, and clinical outcomes (e.g., symptom reduction) are highest-value. Regulators and AI developers prioritize longitudinal sequences showing patient journey evolution.
Can I sell patient data directly, or must it be aggregated?
Data must be fully anonymized and aggregated. Regulatory compliance (GDPR, HIPAA) and FDA/EMA standards require removal of all personal identifiers. Buyers accept only de-identified, aggregated datasets or longitudinal cohorts with strict governance.
Who pays the most for this data?
Pharmaceutical manufacturers preparing regulatory submissions or validating new digital products pay premium rates. Payers running large pilot programs and competing digital therapeutics platforms seeking competitive benchmarks also bid high.
Do I need FDA clearance to collect and sell this data?
Collection itself does not require FDA clearance, but the app delivering treatment must be classified appropriately. Data monetization must comply with privacy laws (HIPAA, GDPR) and contractual consent terms. Buyers often require audit trails confirming regulatory and ethical compliance before purchase.
Sell yourdigital therapeutics usagedata.
If your company generates digital therapeutics usage data, AI companies are actively looking for it. We handle pricing, compliance, and buyer matching.
Request Valuation